Diagnostic products maker Gen-Probe Inc. (NASDAQ:GPRO) has secured the approval of the U.S. Food and Drug Administration (“FDA”) for its PROGENSA PCA3 assay, a novel molecular test designed to aid the diagnosis of prostate cancer.
The assay is geared for testing urine specimens from men who earlier had a negative prostate biopsy.
Gen-Probe submitted a Pre-market Approval (“PMA”) application to the FDA for PROGENSA PCA3 in September 2010. The California-based company, in November 2011, said that … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards